Szabó Mónika, Veres Zsuzsa, Bátai-Konczos Attila, Kékesi Orsolya, Kis Emese, Szabó Kitti, Jemnitz Katalin
Institute of Molecular Pharmacology, Research Centre for Natural Sciences, HAS, 1117 Budapest, Magyar Tudósok körútja 2, Hungary.
Solvo Biotechnology, 6726 Szeged, Közép fasor 52, Hungary.
Toxicol In Vitro. 2014 Sep;28(6):1136-43. doi: 10.1016/j.tiv.2014.05.016. Epub 2014 Jun 6.
Several studies have reported that statins occasionally cause impairment of liver functions characterized by elevated serum bilirubin levels, which might be due to altered function of the multidrug resistance-associated proteins (Mrp2/3). We aimed to study the modulation of the hepatobiliary transport of bilirubin by four statin derivatives, atorvastatin, fluvastatin, pravastatin, and rosuvastatin in sandwich-cultured rat hepatocytes. All statins except pravastatin significantly inhibited the uptake of bilirubin. The biliary efflux of bilirubin conjugates was increased by pravastatin and rosuvastatin concentration dependently. Rosuvastatin stimulated not only the Mrp2 mediated biliary, but the Mrp3 mediated sinusoidal elimination, resulting in decreased intracellular bilirubin accumulation. The significantly induced Mrp2/3 protein levels (ranging from 1.5 to 1.8-fold) accounted for the elevated efflux. Cell polarization, the formation of biliary network was also significantly increased by fluvastatin, pravastatin and rosuvastatin (151%, 216% and 275% of the control, respectively). The simultaneous inhibition of the uptake and the stimulation of the sinusoidal and canalicular elimination may explain, at least in part, the clinical observation of elevated serum bilirubin levels. In conclusion, our results suggest that in spite of the elevated serum bilirubin levels, the altered Mrp2 and Mrp3 functions by statins is probably not associated with hepatotoxic effects.
多项研究报告称,他汀类药物偶尔会导致肝功能损害,其特征为血清胆红素水平升高,这可能是由于多药耐药相关蛋白(Mrp2/3)功能改变所致。我们旨在研究四种他汀类衍生物,即阿托伐他汀、氟伐他汀、普伐他汀和瑞舒伐他汀对三明治培养的大鼠肝细胞中胆红素肝胆转运的调节作用。除普伐他汀外,所有他汀类药物均显著抑制胆红素的摄取。普伐他汀和瑞舒伐他汀可浓度依赖性地增加胆红素结合物的胆汁流出。瑞舒伐他汀不仅刺激Mrp2介导的胆汁流出,还刺激Mrp3介导的窦状隙清除,导致细胞内胆红素积累减少。Mrp2/3蛋白水平显著诱导(1.5至1.8倍)导致流出增加。氟伐他汀、普伐他汀和瑞舒伐他汀也显著增加了细胞极化和胆管网络的形成(分别为对照组的151%、216%和275%)。摄取的同时抑制以及窦状隙和胆小管清除的刺激可能至少部分解释了血清胆红素水平升高的临床观察结果。总之,我们的结果表明,尽管血清胆红素水平升高,但他汀类药物引起的Mrp2和Mrp3功能改变可能与肝毒性作用无关。